Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis

Multiple Sclerosis : Clinical and Laboratory Research
Francesca RinaldiPaolo Gallo

Abstract

Since cortical pathology has been indicated to play a relevant role in the physical and cognitive disability of multiple sclerosis (MS) patients, this study aims to analyze the efficacy of natalizumab in slowing down its progression. A total of 120 relapsing-remitting MS patients completed a 2-year prospective study: 35 received natalizumab, 50 received interferon beta-1a or glatiramer acetate (immunomodulatory agents - IMA) and 35 remained untreated. Forty healthy subjects constituted the reference population. Clinical and magnetic resonance imaging (MRI) evaluations (including cortical lesions and atrophy) were performed at baseline and after 2 years. Natalizumab significantly reduced accumulation of new cortical lesions (0.2±0.6,range 0-3) compared to immunomodulatory agents (1.3±1.1 togli spazio, range 1-6, p=0.001) and no treatment (2.9±1.5, range 1-8, p<0.001). The percentage of patients with new cortical lesions was also lower in natalizumab-treated patients (20%) compared to IMA-treated and untreated patients (68.0% and 74.2%; p<0.001 for both comparisons). Furthermore, the progression of cortical atrophy was significantly reduced by natalizumab (% change=1.7%) compared to IMA (3.7%, p=0.003) and no therapy (4.6%, p<0.0...Continue Reading

References

Aug 1, 1991·Journal of Neurology, Neurosurgery, and Psychiatry·D H MillerA J Thompson
Mar 2, 1999·Brain : a Journal of Neurology·D KiddT Revesz
Sep 14, 2000·Proceedings of the National Academy of Sciences of the United States of America·B Fischl, A M Dale
Jun 1, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·R ZivadinovM Zorzon
Jun 5, 2002·Current Opinion in Neurology·Frederik Barkhof
Jun 14, 2003·Brain : a Journal of Neurology·Michael SailerAnders Dale
Oct 19, 2005·Brain : a Journal of Neurology·Alexandra KutzelniggHans Lassmann
Nov 12, 2005·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Feb 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·S Martínez-YélamosTx Arbizu
Apr 25, 2007·Neurology·D H MillerUNKNOWN AFFIRM Investigators
Jan 30, 2008·Journal of Neurology·Massimiliano CalabresePaolo Gallo
May 20, 2008·Lancet Neurology·Andreas Lutterotti, Roland Martin
Aug 30, 2008·Multiple Sclerosis : Clinical and Laboratory Research·M CalabreseP Gallo
May 14, 2009·Multiple Sclerosis : Clinical and Laboratory Research·S D RoosendaalJ J G Geurts
Sep 16, 2009·Archives of Neurology·Massimiliano CalabreseMassimo Filippi
Jun 11, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·F RinaldiP Gallo
Dec 16, 2010·Journal of Surgical Education·Jay M Macgregor, Robert Sticca
Jan 5, 2011·Annals of Neurology·Samia Khoury, Rohit Bakshi
May 18, 2011·Neurology·B F Gh PopescuC F Lucchinetti
Dec 14, 2011·The New England Journal of Medicine·Claudia F LucchinettiRichard M Ransohoff

❮ Previous
Next ❯

Citations

Jul 24, 2013·Multiple Sclerosis International·Justin Morris Honce
Jan 20, 2016·Neurodegenerative Disease Management·Eva Costa ArpínManuela Lema Bouzas
Dec 18, 2012·Journal of Neuropathology and Experimental Neurology·Roberta MagliozziFrancesca Aloisi
Jun 5, 2015·Journal of Neurology·Angela Vidal-JordanaXavier Montalban
Feb 26, 2014·Current Opinion in Pharmacology·Paul M Matthews, Olivia C Geraghty
May 5, 2016·The International Journal of Neuroscience·Fariha KhalidRohit Bakshi
Aug 15, 2015·Journal of Neurology, Neurosurgery, and Psychiatry·Varun SethiDeclan T Chard
Jan 21, 2016·Therapeutic Advances in Neurological Disorders·Finn SellebjergDaniel Mikol
Jun 30, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Ethel CiampiXavier Montalban
Nov 14, 2014·Multiple Sclerosis : Clinical and Laboratory Research·J Sastre-GarrigaX Montalban
Aug 26, 2018·Brain and Behavior·Allan MacKenzie-GrahamRhonda R Voskuhl
May 6, 2014·Current Opinion in Neurology·Massimo FilippiMaria A Rocca
Aug 28, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Paolo PreziosaMassimo Filippi
Mar 1, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·Paolo PreziosaMassimo Filippi
Jun 30, 2018·Neurology and Therapy·Maria PetraccaMatilde Inglese
Apr 8, 2020·Auto- Immunity Highlights·Athina AndravizouGeorgios M Hadjigeorgiou

❮ Previous
Next ❯

Software Mentioned

FreeSurfer
SPSS
R

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Francesca RinaldiPaolo Gallo
Journal of Neurology, Neurosurgery, and Psychiatry
Varun SethiD T Chard
Multiple Sclerosis : Clinical and Laboratory Research
M CalabresePaolo Gallo
© 2021 Meta ULC. All rights reserved